Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 11Recruiting 7Unknown 4Terminated 2Withdrawn 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 20Lymphoma, Large B-Cell, Diffuse 16Lymphoma 14Neoplasms 13Sarcoma 10Hodgkin Disease 10Triple Negative Breast Neoplasms 9Lymphoma, Follicular 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell 7Ovarian Neoplasms 6Burkitt Lymphoma 6Lymphoma, Non-Hodgkin 5Fallopian Tube Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Sarcoma, Ewing 3Recurrence 3Leiomyosarcoma 3Inflammatory Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neurofibrosarcoma 2Neuroblastoma 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2romidepsin 1decitabine and cedazuridine drug combination 1Vincristine 1Tomography, X-Ray Computed 1Prednisone 1Oxaliplatin 1Gemcitabine 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell, Peripheral × Doxorubicin × Clear all
NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡